SCHEDULE 13G/A: Anson Funds Group Discloses 4.5% Passive Stake in 180 Life Sciences Corp.

Anson Funds Management LP and its affiliated entities have filed an amendment to disclose a 4.5% beneficial ownership stake in 180 Life Sciences Corp., held for ordinary business purposes.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam collectively reported beneficial ownership of 245,750 shares of Common Stock in 180 Life Sciences Corp.
• This aggregate amount represents 4.5% of the outstanding class of Common Stock.
• The percentage is calculated based on 5,431,530 total shares, which includes 5,185,780 shares issued and outstanding as of May 8, 2025, and 245,750 shares receivable upon the exercise of warrants held by the reporting persons.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard regulatory disclosure by an investment group, indicating a passive ownership stake in a publicly traded company. It does not provide insights into broader industry trends or competitive positioning of 180 Life Sciences Corp. itself.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership by an investment group, confirming that the stake is not intended to influence control.

Key Dates

Keywords

180 Life Sciences Corp., Anson Funds Management LP, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Passive Investment